Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine the safety of clevidipine for treating severely
elevated blood pressure, defined as systolic (SBP) >180 mmHg and/or diastolic blood pressure
(DBP) >115 mmHg assessed on 2 successive occasions 15 minutes apart at baseline, in patients
with or without major organ injury, particularly with respect to controlled dose adjustment
to desired effect and prolonged continuous infusion. Enrollment of patients into the study
was to continue until the target goal of 100 patients with at least 18 hours of continuous
clevidipine treatment, including a minimum of 50 patients with acute or chronic end-organ
injury, was met.